Cited 0 times in
Application of precision medicine based on next-generation sequencing and immunohistochemistry in ovarian cancer: a real-world experience
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김성훈 | - |
dc.contributor.author | 박은향 | - |
dc.contributor.author | 이승태 | - |
dc.contributor.author | 이정윤 | - |
dc.contributor.author | 이지현 | - |
dc.contributor.author | 김유나 | - |
dc.contributor.author | 이지현 | - |
dc.date.accessioned | 2023-11-07T07:51:59Z | - |
dc.date.available | 2023-11-07T07:51:59Z | - |
dc.date.issued | 2023-06 | - |
dc.identifier.issn | 2005-0380 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/196544 | - |
dc.description.abstract | Objective: To evaluate the landscape of gene alterations and immunohistochemistry (IHC) profiles of patients with ovarian cancer for targeted therapy and investigate the real-world experience of applying precision medicine. Methods: Patients diagnosed with ovarian cancer between January 2015 and May 2021 at Severance Hospital and who underwent tumor next-generation sequencing (NGS) were reviewed. Data on germline mutation, IHC markers for mismatch repair deficiency (MMRd), programmed death ligand 1 (PD-L1) expression, and human epidermal growth factor receptor 2 (HER2) expression were acquired. The use of matched therapy and its clinical outcomes were evaluated. Results: Of the 512 patients who underwent tumor NGS, 403 underwent panel-based germline testing. In patients who underwent both tests, tumor NGS identified 39 patients (9.7%) with BRCA mutations and 16 patients (4.0%) with other homologous recombination repair (HRR)-associated gene mutations, which were not found in germline testing. The most common single nucleotide variants were TP53 (82.2%), ARID1A (10.4%), PIK3CA (9.7%), and KRAS (8.4%). Copy number aberrations were found in 122 patients. MMRd was found in 3.2% of patients, high PD-L1 expression in 10.1%, and HER2 overexpression in 6.5%. Subsequently, 75 patients (14.6%) received a poly (ADP-ribose) polymerase inhibitor based on BRCA mutation and 11 patients (2.1%) based on other HRR-associated gene mutations. Six patients (1.2%) with MMRd underwent immunotherapy. Twenty-eight patients (5.5%) received other matched therapies targeting HER2, fibroblast growth factor receptor, folate receptor alpha, RAS, and PIK3CA. Conclusion: A comprehensive review of germline mutation, IHC, and tumor NGS helped identify candidates for precision therapy in patients with ovarian cancer, a proportion of whom received matched therapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Asian Society of Gynecologic Oncology : Taehan Puin Chongyang Hakhoe | - |
dc.relation.isPartOf | JOURNAL OF GYNECOLOGIC ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Application of precision medicine based on next-generation sequencing and immunohistochemistry in ovarian cancer: a real-world experience | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Obstetrics and Gynecology (산부인과학교실) | - |
dc.contributor.googleauthor | Yoo-Na Kim | - |
dc.contributor.googleauthor | Yun Soo Chung | - |
dc.contributor.googleauthor | Ji Hyun Lee | - |
dc.contributor.googleauthor | Eunhyang Park | - |
dc.contributor.googleauthor | Seung-Tae Lee | - |
dc.contributor.googleauthor | Sunghoon Kim | - |
dc.contributor.googleauthor | Jung-Yun Lee | - |
dc.identifier.doi | 10.3802/jgo.2023.34.e70 | - |
dc.contributor.localId | A00595 | - |
dc.contributor.localId | A05760 | - |
dc.contributor.localId | A04627 | - |
dc.contributor.localId | A04638 | - |
dc.contributor.localId | A06064 | - |
dc.relation.journalcode | J01428 | - |
dc.identifier.eissn | 2005-0399 | - |
dc.identifier.pmid | 37417298 | - |
dc.subject.keyword | Biomarkers | - |
dc.subject.keyword | High-Throughput Nucleotide Sequencing | - |
dc.subject.keyword | Molecular Targeted Therapy | - |
dc.subject.keyword | Ovarian Neoplasms | - |
dc.subject.keyword | Precision Medicine | - |
dc.contributor.alternativeName | Kim, Sung Hoon | - |
dc.contributor.affiliatedAuthor | 김성훈 | - |
dc.contributor.affiliatedAuthor | 박은향 | - |
dc.contributor.affiliatedAuthor | 이승태 | - |
dc.contributor.affiliatedAuthor | 이정윤 | - |
dc.contributor.affiliatedAuthor | 이지현 | - |
dc.citation.volume | 34 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | e70 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GYNECOLOGIC ONCOLOGY, Vol.34(6) : e70, 2023-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.